ArticleCancer medicine2025
Prognostic Stratification of Initial Treatments for Hepatocellular Carcinoma Using a Modified Borderline Resectable Classification.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimAlthough Japanese expert consensus introduced the borderline resectable (BR) criteria, additional classification is considered necessary for clinical practice. This study aimed to evaluate the prognostic predictive value of the modified BR (mBR) criteria.
methodsFrom 2009 to 2024, 1056 treatment-naïve patients with hepatocellular carcinoma (HCC) and Child-Pugh A were enrolled (median age: 73 years). To obtain the mBR criteria, the original BR classification was modified by separately considering patients with extrahepatic metastasis (EHM, termed "boldly BR") (n = 42) while categorizing the rest into resectable (n = 790), mBR1 (n = 95), and mBR2 (n = 129) groups. Treatments were classified as Cur (curative: surgical resection or radiofrequency ablation), NC (non-curative: other treatment), or BSC (best supportive care). Clinical features and prognosis according to mBR criteria were analyzed retrospectively.
resultsOverall survival (OS) was stratified according to the mBR criteria (resectable/mBR1/mBR2/BBR = 113.3/49.4/30.1/10.3 months). Albumin-bilirubin scores worsened progressively, according to the criteria (-2.70/-2.54/-2.40/-2.37), and elevated tumor marker levels (alpha-fetoprotein [AFP] levels ≥ 100 ng/mL: 18.5%/35.8%/46.5%/59.5%; AFP-L3 ≥ 10%: 19.8%/40.9%/54.7%/66.7%; and des-gamma-carboxy prothrombin levels ≥ 100 mAU/mL: 35.8%/67.4%/81.4%/90.5%, each p < 0.001) occurred more frequently in advanced groups. The Cur group in the resectable category showed significantly better OS compared with the NC and BSC groups (121.3/48.1/35.3 months, p < 0.001). Similar trends occurred in mBR1 (66.5/34.2/5.2 months) and mBR2 (57.3/22.4/7.5 months). Conversely, although some patients in the curative group had long-term survival, treatment modality and baseline characteristics showed no prognostic impact on BBR (15.0/10.3/9.0 months).
conclusionOther than for patients with EHM, aggressive surgical resection may be considered a potential initial therapeutic option for advanced HCC; however, direct comparisons with other treatment modalities were not performed in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.